文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

自体T细胞疗法治疗HLA-A*02阳性患者的MAGE-A4阳性实体瘤:一项1期试验

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.
PubMed 文献 · Nat Med · 2023-01-09

这项多中心、剂量递增1期试验评估了靶向MAGE-A4的afamitresgene autoleucel(afami-cel)在复发/难治性转移性实体瘤患者中的安全性和疗效。全部38例患者均出现≥3级血液学毒性,55%发生细胞因子释放综合征(90%为≤2级)。总缓解率为24%(9/38),滑膜肉瘤为44%(7/16),其他癌症为9%(2/22)。

要点

  • 全部38例患者出现≥3级血液学毒性,55%发生细胞因子释放综合征(90%为≤2级)。
  • 总缓解率24%(9/38),滑膜肉瘤44%(7/16),其他癌症9%(2/22)。
  • 总缓解持续时间中位25.6周,滑膜肉瘤28.1周,早期且持久缓解。

核心结论

  • afami-cel具有可接受的获益-风险特征,尤其在转移性滑膜肉瘤患者中可见早期且持久的缓解;但试验样本量小限制了可得出的结论,结果需要在更大规模研究中进一步验证。

研究设计与样本

  • 多中心、剂量递增、1期试验,纳入复发/难治性转移性表达MAGE-A4的实体瘤患者(包括滑膜肉瘤、卵巢癌和头颈癌),共38例、9种肿瘤类型,主要终点为安全性。

主要发现

  • 全部患者(N=38)出现≥3级血液学毒性;55%的患者发生细胞因子释放综合征(其中90%为≤2级)。
  • 总缓解率(均为部分缓解)为24%(9/38),滑膜肉瘤为44%(7/16),所有其他癌症为9%(2/22)。
  • 总缓解持续时间中位为25.6周(95%CI:12.286,未达到),滑膜肉瘤为28.1周(95%CI:12.286,未达到)。
  • 探索性分析显示afami-cel可浸润肿瘤,具有干扰素-γ驱动的作​​用机制,并触发适应性免疫应答。

局限性

  • 试验样本量小限制了可得出的结论。
  • 结果需要在更大规模研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), a cancer/testis antigen expressed at varying levels in multiple solid tumors. We conducted a multicenter, dose-escalation, phase 1 trial in patients with relapsed/refractory metastatic solid tumors expressing MAGE-A4, including synovial sarcoma (SS), ovarian cancer and head and neck cancer ( NCT03132922 ). The primary endpoint was safety, and the secondary efficacy endpoints included overall response rate (ORR) and duration of response. All patients (N = 38, nine tumor types) experienced Grade ≥3 hematologic toxicities; 55% of patients (90% Grade ≤2) experienced cytokine release syndrome. ORR (all partial response) was 24% (9/38), 7/16 (44%) for SS and 2/22 (9%) for all other cancers. Median duration of response was 25.6 weeks (95% confidence interval (CI): 12.286, not reached) and 28.1 weeks (95% CI: 12.286, not reached) overall and for SS, respectively. Exploratory analyses showed that afami-cel infiltrates tumors, has an interferon-γ-driven mechanism of action and triggers adaptive immune responses. In addition, afami-cel has an acceptable benefit-risk profile, with early and durable responses, especially in patients with metastatic SS. Although the small trial size limits conclusions that can be drawn, the results warrant further testing in larger studies.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Hong DS, Van Tine BA, Biswas S, et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat Med. 2023. PMID: 36624315. doi:10.1038/s41591-022-02128-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。